Prostate Cancer Discovered in 40 Percent of Men Who Test Negative for the Disease

WESTMONT, Ill., Dec. 15 Forty percent of men with prostatecancer may not even know they have it, according to a new research study bythe Prostate Cancer Foundation of Chicago. The study revealed the standardoffice biopsy procedure often isn't enough to properly detect prostate cancer.This new research will be published in an upcoming issue of Urology, anational medical journal.

Researchers used an advanced biopsy technique called stereotactictransperineal prostate biopsy (STPB). This was performed on patients withpersistent elevated prostate specific antigen (PSA) levels who previously hadat least one negative office biopsy. All patients had received transrectalprostate biopsies (TRPB), administered by a urologist.

"Men who have negative transrectal biopsies and continue to have elevatedPSA levels should consider STPB because 40% will harbor malignancy," saysMichelle Braccioforte, director of research and education for the ProstateCancer Foundation of Chicago. "Our level of confidence is greatly enhancedwith regards to the presence or absence of cancer, and more specifically, theexact location of the cancer within the prostate."

STPB is performed by taking a median of 40 samples of the prostate throughthe perineum while the patient is under general anesthesia. Performed as anoutpatient procedure, it allows more comprehensive sampling, compared to thetransrectal method, which takes fewer samples through the rectum. Inaddition, by taking more samples during STPB, the exact location of the cancercan be pinpointed.

Between April 2004 and January 2008, 747 patients with high PSA levelswere studied. All patients had been tested using TRPB at least once and allresults had been negative. All patients received the STPB. Biopsy resultsidentified the presence of cancer in 291 (39%) of the patients.

One in six men in the U.S. will be diagnosed with prostate cancer, themost common form of cancer among men. For those with elevated or rising PSAlevels, this is a sign that further testing should be administered to rule outprostate cancer.

The Prostate Cancer Foundation of Chicago, located in Westmont, IL, is anot-for-profit organization that conducts ongoing research intended to improvethe diagnosis and treatment of prostate cancer. For more information, visithttp://www.chicagoprostatefoundation.org to download or call Michelle at630.654.2515.

SOURCE The Prostate Cancer Foundation of Chicago

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...